Stock-exchange announcement
For media and investors only

Issued: 20 November 2025, London UK

TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc.

GSK plc (LSE/NYSE: GSK) subsidiary, TESARO, Inc., confirms it has initiated litigation against AnaptysBio, Inc. in the Delaware Chancery Court. This action contends that recent conduct by AnaptysBio is in material breach of the existing license agreement with TESARO regarding the oncology treatment *Jemperli* (dostarlimab). The breach entitles TESARO to terminate the current license agreement, obtain a perpetual and irrevocable license to dostarlimab, and to reduce the royalties and milestone payments due by TESARO to AnaptysBio by 50%.

TESARO has initiated this litigation following allegations made by AnaptysBio that TESARO has not fulfilled certain requirements of the license agreement entered in March 2014 and that AnaptysBio intends to revoke TESARO's licence for dostarlimab. GSK and TESARO are firmly of the view that these allegations are entirely without merit.

Jemperli is currently approved in over 35 countries for use in certain endometrial cancers, the most common gynaecologic cancer in the United States. GSK and TESARO have reported significant growth for *Jemperli* driven by label expansions in endometrial cancer, including in the US and EU. A robust and ambitious clinical trial programme to evaluate the potential use of dostarlimab in additional cancers, including rectal, colon and head and neck, is ongoing.

About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

GSK enquiries

Media:	Tim Foley	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Sam Piper	+44 (0) 7824 525779	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Registered in England & Wales:
No. 3888792

Registered Office:
79 New Oxford Street
London
WC1A 1DG